Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Research on Tenofovir (Viread)

HIV Treatment Research | Tenofovir for HIV Prevention

Show Archived (Historical) Articles

HIV Treatment Research

Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV (April 17, 2009)
Study will assess safety and efficacy of single-tablet regimen containing elvitegravir boosted by GS 9350 and Truvada compared to Atripla.
From Gilead Sciences, Inc.
Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds (February 9, 2009)
Walid Heneine, Ph.D., explains the results of a study in macaques which found that a topical gel offered complete protection against SIV infection -- regardless of whether that gel contained tenofovir alone or tenofovir in combination with emtricitabine.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com
Tenofovir Shows Excellent Promise as a Treatment for Hepatitis B Monoinfection (April 25, 2008)
From aidsmap.com
Major Study Finds Red Flags When Using Epzicom as First-Line Therapy in People With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases
Tenofovir Appears Effective Against HIV and Hepatitis B in Coinfected People (June 12, 2007)
From aidsmap.com
Link Between Tenofovir and Renal Toxicity Remains Tenuous, but Monitoring Is Warranted (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
HIV JournalView: Risk of Tenofovir Nephrotoxicity May Be Real, Though Murky (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.